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Objectives: Irritable bowel syndrome (IBS) can be diagnosed clinically and man-
aged within primary care, yet around 25% of patients are referred to gastroen-
terology. The objective of this study was to estimate the cost-effectiveness of a 
gastroenterology outpatient appointment for IBS from the perspective of the health 
service payer (UK NHS) over a three year time horizon. MethOds: Individual level 
healthcare utilization data were extracted for 2076 IBS patients within the UK 
Clinical Practice Research Dataset with linked Hospital Episode Statistics data who 
first visited a gastroenterologist in 2008 or 2009. Individual costs of total health-
care utilization were calculated for three years before and after gastroenterology 
attendance in 2012 UK£. Quality Adjusted Life Years (QALYs) were modeled from 
utility values reported in a questionnaire study of 69 patients with IBS attending 
a gastroenterology outpatient clinic for the first time. Costs and QALYs before the 
appointment were used to represent costs in the absence of seeing a gastroenter-
ologist. Mean cost per QALY of a gastroenterology appointment compared to no 
referral over three years produced the incremental cost effectiveness ratio (ICER). 
Bootstrapping generated a 95% confidence interval (CI). Net-benefit analysis gen-
erated a Cost Effectiveness Acceptability Curve (CEAC). Scenario and probabilistic 
sensitivity analyses assessed structural and parameter uncertainty. Results: 
The expected QALY gain for a gastroenterology appointment for IBS compared to 
no appointment was 0.14. The expected extra total healthcare costs were £3002. 
The ICER was £21767.08/QALY (95% CI £17078/QALY to £26495/QALY). Likelihood 
of cost-effectiveness at a threshold of £20000/QALY was 25% and 100% at £30000/
QALY. Lower expected QALYs following appointment increases the ICER to £34550/
QALY. cOnclusiOns: Depending on the level of the cost-effectiveness threshold, 
referral to a secondary care gastroenterologist for IBS could be cost-effective for the 
NHS but more robust data on potential QALY gains are needed.
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Objectives: To evaluate the cost-effectiveness of 10mg ilaprazole once daily vs. 
20 mg omeprazole once daily to treat newly diagnosed duodenal ulcer patients in 
China. MethOds: A decision tree model was constructed and the treatment impact 
was projected up to one year. The CYP2C19 polymorphism distribution in the Chinese 
population, the respective cure rates in the CYP2C19 genotype subgroups, the impact 
of duodenal ulcer on utility, and drug related side effects data were obtained from 
literature. The total cost of medications were calculated to estimate treatment costs 
based on current drug retail prices in China. Expert survey was conducted when 
published data were not available to populate the model such as costs of the side 
effects. The main summary measure in this evaluation was incremental cost per 
quality-adjusted life-years (QALY) gained. Probabilistic sensitivity analysis was per-
formed to determine the robustness of the results. Results: Ilaprazole achieved a 
better overall efficacy, because it is less impacted by CYP2C19 genotype subgroups. 
Compared with omeprazole, ilaprazole achieved an incremental cost effectiveness 
ratio of ¥138,941 per QALY gained which is less than the 3 times of China average GDP 
per capital (2014). A subgroup analysis suggests Ilaprazole is most cost-effective in 
the CYP2C19 subpopulation of heterogeneous extensive metabolizer, which had the 
incremental cost effectiveness ratio of ¥60,824 per QALY gained. Probabilistic sensitiv-
ity analysis suggests that the results are robust with 95% probability that ilaprozole 
is consider cost effective when 3 times China average GDP per capital threshold 
is used. cOnclusiOns: The cost-effectiveness analysis results demonstrated that 
ilaprazole would be considered cost-effective compared with omeprazole to treat 
newly diagnosed duodenal ulcer patient in China. When treating the duodenal ulcer 
patients who are CYP2C19 subpopulation of heterogeneous extensive metabolizer, 
ilaprazole is highly cost-effective, compared with omeprazole.
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Objectives: The aim of the study was to compare the cost-effectiveness of esome-
prazole with other PPIs currently reimbursed in Poland in the acute treatment of 
gastroesophageal reflux disease (GERD). MethOds: A decision analysis model 
simulating the treatment of GERD over the course of 8 weeks was developed. The 
duration of treatment is in line with the one recommended by the general guide-
lines. Healing rates were pooled from the existing clinical trials comparing esome-
prazole with other PPIs. All patients were initially treated with PPI at high-dose for 
4 weeks. Subsequently, healing was verified by the gastroenterologist and upper 
gastrointestinal endoscopy. Patients with treatment success at 4 weeks started 
maintenance treatment with a low-dose PPI and were assumed to remain healed 
for the duration of the model. Patients unhealed at 4 weeks were prescribed a fur-
ther 4-week treatment course with the same high-dose of PPI, followed by a second 
visit with endoscopy was carried out. The analysis was conducted from a public 
payer perspective. Cost of PPIs was derived from the publicly available Ministry of 
Health (MoH) price list. Gastroenterologist visit and endoscopy were estimated on 
the basis of National Health Fund (NHF) data. Data are presented in EUR (1 EUR = 
4.00 PLN). Results: Over the course of 8 weeks, treatment with esomeprazole was 
projected to have slightly better net clinical benefits over treatment with lansopra-
Objectives: To determine the focus of research on economic burden in gas-
trointestinal disorders from studies published in 2014. MethOds: An evidence 
surveillance process was established based on a systematic search of PubMed, 
incorporating all studies published from 2010 and updated weekly, with a final 
search on 1 June 2015. Abstracts identified by the search for costs or resource use 
outcomes in gastrointestinal disorders were identified. Articles were included 
if they reported results from a primary research study, systematic review or 
economic model. Economic outcomes were identified, where possible, from the 
abstract alone. Results: The economic burden search identified 1,870 articles 
published in 2014, with 968 meeting the inclusion criteria for any disease. Of 
these, 88 (9%) were in gastrointestinal disorders, based on ICD-10 classifications. 
Almost half (41 articles) were observational studies, 32 were RCTs or comparative 
studies, 11 were economic evaluations and 4 were literature reviews. Most of the 
studies were relevant to surgical procedures for colorectal surgery (13 articles), 
gall stones or cholecystitis (11), appendicitis (7) or hernia repair (7), with 12 arti-
cles reporting dental procedures. Only eleven articles reported costs or resource 
use associated with medical treatment, mainly for inflammatory bowel disease 
(6 articles) or peptic ulcer (2). The USA was the most common setting, based on 
abstract text or author affiliations (27 articles), followed by the UK (7), Italy and 
China (6 each) and Spain (4). Indirect costs were reported in only 9 articles, of 
which 3 reported productivity losses. No abstract reported caregiver or social care 
costs. Direct costs were evaluated in 60 articles and healthcare resource use in 69 
articles. cOnclusiOns: Recent research on economic burden in gastrointestinal 
disorders has focused disproportionately on direct costs and resource use associ-
ated with surgical procedures. Up-to-date data on indirect costs, and direct costs 
of non-surgical interventions, remains sparse.
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Objectives: The aim of this study is determine the persistence and economic 
impact of Adalimumab (ADA) discontinuation in inflammatory bowel disease (IBD) 
patients with at least 6 months in Sustained Clinical Remission (SCR). MethOds: 
We conducted an observational and retrospective study to assess the persistence 
and economic impact of ADA discontinuation treatment after achieving SCR in IBD 
patients between Jan2009-May 2015. Eligible IBD patients were > 18 years in SCR on 
ADA by maintenance treatment of 40 mg/14days for a minimum of 6 months. We 
collected age, sex, indication, persistence (years) of ADA treatment, ADA discontinu-
ation period (years) and if there was an IBD relapse after the ADA discontinuation. 
We determined the real cost of ADA treatment for each patient from invidualized 
drug dispensations and correlated dates during the study period. The cost sav-
ings obtained during the patients ADA discontinuation was calculated using the 
ADA cost per day for each patient by the days of each patient in complete remis-
sion. Results: From Jan 2009 to May 2015, 18 patients (83% women; age 39±10 
years; 15 Crohn Disease and 3 Ulcerative Colitis) discontinued ADA therapy. These 
patients were on ADA therapy for 2.1±1.2 years towards achieve SCR and stopped 
ADA therapy. The persistence of these patients in SCR (discontinued ADA therapy) 
was 2.3±0.9 years; range 1.1-3.8 years. 6 (33%) patients had an IBD relapsed and 
restarted ADA therapy. During the study period, the total associated ADA costs for 
all IBD patients included was 477.313€ with an ADA patient daily cost of 37.7±12.5€ . 
The implementation of the strategy of ADA discontinuation in IBD patients in SCR 
for at least 6 months produced a cost savings of 520.522,7€ thorough the study 
period. cOnclusiOns: Discontinuation ADA treatment in IBD patients in SCR for 
at least 6 months could make treatment more cost-effective and allow gastroen-
terologists to treat more patients with a fixed budget.
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Objectives: To map resource use and associated costs of managing chronic hepatitis 
C (CHC) in Greece across all disease stages and discuss simeprevir (SMV) in combina-
tion with pegylated-interferon + ribavirin (PR) as a potential treatment option in the 
early stages. MethOds: An expert panel of 8 leading hepatologists determined local 
resource use for CHC. Unit costs were obtained from officially published sources. 
Direct costs (medical, hospital, lab and imaging tests, and pharmaceutical care exclud-
ing anti-viral treatment) were estimated for each of the following health states of the 
disease: non-cirrhotic CHC, compensated cirrhosis, decompensated cirrhosis, hepa-
tocellular carcinoma (HCC) and liver transplantation. Productivity losses were also 
included in the analysis. The perspective was that of the Social Insurance Fund (SIF) 
and the cost base year was 2014. Results: The costs associated with non-cirrhotic 
CHC and compensated cirrhosis were estimated at € 84.65 and € 128.85, respectively, 
consisting mainly of lab and imaging tests. Medical follow up for CHC patients across 
all stages is performed through public hospital outpatient units, without entailing 
costs for SIFs. The annual per patient costs for decompensated cirrhosis, HCC and 
liver transplant were estimated at € 3,170.20, € 8,513.22 and € 129,412, respectively and 
consisted mainly of hospitalization costs. Indirect costs were estimated at € 1,009 for 
both non-cirrhotic and compensated cirrhosis stages, and at € 4,539 for decompen-
sated cirrhosis. cOnclusiOns: Costs of managing CHC increase dramatically with 
disease severity. A recent publication from the UK supports the cost-effectiveness of 
SMV+PR against PR, with an ICER of £9,725/ QALY for treatment-naïve and £7,819/ 
QALY for treatment-experienced patients. Therefore and under the current cost con-
tainment environment in Greece, SMV+PR could be a cost-effective treatment option 
for treating patients earlier to prevent high costs at later stages.
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review articles for cost-effectiveness studies of ulcerative colitis (UC) and to evaluate 
analytical approaches that can be applied to Japanese environment. MethOds: The 
literature search was conducted in MEDLINE and JDream III. Inclusion criteria are 
studies of 1) treatment for UC, 2) cost-effectiveness analysis (CEA), 3) published in 
the past 10 years. Studies were assessed for the followings: country, model struc-
ture and simulation method, time horizon, perspective, source of key parameters, 
results, and key drivers determined from sensitivity analysis. Results: Nine 
studies were reviewed in details. Markov (6 articles) and decision tree (2 articles) 
models were adopted, and time horizon varied from 12 weeks of clinical trial peri-
ods to lifetime. Studies additionally considering surgery and treatment costs of 
colorectal cancer referred to other studies or official medical fees. Utility scores 
were referred to other studies (9 articles). Disutility of surgery was estimated based 
on assumptions. Parameters which became key drivers for these analyses varied 
among studies. cOnclusiOns: Data collection methods adopted in prior studies 
were applicable to CEA for UC in Japan. Cost data can be obtained not only from 
questionnaire survey to doctors but commercial database. Because evidence on 
utility scores of Japanese population is still limited, further studies will be needed, 
especially on patients in different phases of UC treatment.
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Objectives: As of 2014, there were approximately 8,300 patients with a functioning 
liver transplant in the UK Transplant Registry, with 880 liver transplants performed 
in 2013–14 alone. As the number of surviving liver transplant recipients continues to 
increase, healthcare expenditure in these patients should be periodically reviewed 
to maximize value for money. With tacrolimus representing the current cornerstone 
of post-transplant immunosuppressive therapy, the present study objective was to 
evaluate the cost-effectiveness of prolonged-release (PR) tacrolimus versus imme-
diate-release (IR) tacrolimus. MethOds: A model was developed in Microsoft Excel 
to evaluate the cost and effectiveness of immunosuppressive regimens in liver 
transplant recipients. The model captured costs associated with immunosuppres-
sive medications, retransplantation and acute rejection. Three-year patient and graft 
survival data were taken from a recent retrospective European registry analysis and 
initial dose data were taken from the prescribing information. Costs were taken from 
the British National Formulary and the National Health Service National Tariff and 
expressed in 2014 pounds sterling. Results: Over a 3 year time horizon, the number 
needed to treat (NNT) with PR tacrolimus relative to IR tacrolimus was ~13 to avoid 
one graft loss and 17 to avoid one death. The model was sensitive to dosing assump-
tions, with incremental cost estimates varying between a saving of GBP 2,236 per 
treated patient, assuming the same dosing of PR and IR (per kilogram bodyweight) 
and an increase of GBP 781 using RCT dose data. cOnclusiOns: Data from a recent 
analysis of routine clinical practice data in liver transplant recipients on PR and IR 
tacrolimus showed significant differences in long-term graft survival in favor of PR 
tacrolimus. Modeling these data in a UK population showed that, over a three-year 
time horizon one graft would be saved for approximately every 13 patients treated 
with PR tacrolimus with minimal impact on costs.
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Objectives: Hepatic encephalopathy (HE) is associated with high morbidity and 
mortality. Rifaximin-α 550mg reduces the recurrence of episodes of overt HE. We 
determined the cost effectiveness of rifaximin-α 550mg versus standard care (lactu-
lose) in patients with cirrhosis in the UK. MethOds: This economic evaluation used 
a Markov state transition model. The outcome metric was the ICER, derived from 
estimates of the cost/QALYs. The payer perspective was that of UK National Health 
Service. Outcome data were from two rifaximin-α 550mg trials. Population outcome 
data were from a complementary study of patients with liver cirrhosis treated within 
the NHS. UK Costs data (2012) were derived from published sources. Health-related 
utility was estimated indirectly from disease-specific quality of life RCT data. The 
time horizon was five years. Costs and benefits were discounted at 3.5%. Extensive 
sensitivity analyses were carried out. Real world data describing the use of rifaximin-α 
550mg in the UK NHS were also applied into the model for length of stay in hospital 
and the number of admissions. Results: The average cost for the included elements 
of care was £22,971 for rifaximin-α 550mg and £23,545 for lactulose, a difference of 
-£573. The corresponding values for benefit were 2.36 QALYs/person and 1.83 QALYs/
person, respectively, a difference of 0.53 QALYs. This translated into a dominant base-
case ICER. Key parameters that impacted the ICER included length of stay in hospital 
and the number of admissions to hospital. Evaluation to 10 years and lifetime resulted 
in ICERs of £4,470/QALY and £7,215/QALY, respectively. cOnclusiOns: Rifaximin-α 
550mg in patients with recurrent HE in the context of liver cirrhosis represented good 
value for money compared to standard care, by reducing episodes of overt HE, the 
likelihood of hospital admission and hospital length of stay.
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Objectives: The purpose of this study was to analyze the cost-effectiveness of the 
association of everolimus (EVR) with reduced tacrolimus doses (rTAC) in liver trans-
plantation patients with renal dysfunction. MethOds: A cost-effectiveness analysis 
zole, omeprazole or pantoprazole (the QALY gains were 0.0002, 0.0003 and 0.0003, 
respectively). There were also marginal cost savings achieved by esomeprazole 
(1.23 EUR versus lansoprazole, 2.27 EUR versus omeprazole and 1.51 EUR versus 
pantoprazole), therefore esomeprazole was projected to have a dominant position 
versus other PPIs in the cost-effectiveness analysis. cOnclusiOns: Esomeprazole 
provides greater effectiveness at a lower cost compared with other PPIs currently 
reimbursed in Poland in the treatment of GERD.
PGI21
evalUaTIon of The CosT effeCTIveness of RIfaxImIn-á 550mG In The 
RedUCTIon of ReCURRenCe of oveRT hePaTIC enCePhaloPaThy In 
sWeden
Poole CD1, Berni E2, Conway P3, Radwan A4, Currie CJ1
1Cardiff University, Cardiff, UK, 2Pharmatelligence, Cardiff, UK, 3Norgine Ltd, Harefield, UK, 
4Norgine Ltd, Uxbridge, UK
Objectives: Hepatic encephalopathy (HE) is associated with high morbid-
ity and mortality. Rifaximin-α 550mg reduces the recurrence of episodes of 
overt HE, and hospital utilisation. We characterised the cost effectiveness of 
rifaximin-α 550mg versus standard care (lactulose) in patients with liver cirrhosis 
in Sweden. MethOds: This economic evaluation used a Markov state transition 
model. The outcome metric was the ICER, derived from estimates of the cost/QALYs. 
The payer perspective was that of the Swedish healthcare system. Outcome data 
were from two rifaximin-α 550mg trials. Population outcome data were from a 
complementary study of patients with liver cirrhosis treated in Sweden. Swedish 
Costs data (2012) were derived from published sources. Health-related utility was 
estimated indirectly from disease-specific quality of life RCT data. The time horizon 
was five years. Costs and benefits were discounted at 3.5%. Extensive sensitivity 
analyses were carried out. Real world data were also applied into the model for 
length of stay in hospital and the number of admissions. Results: The average cost 
of the included elements of care was SEK302,520 (€ 32,667) for rifaximin-α 550mg 
and SEK393,777 (€ 42,522) for lactulose, a difference of -SEK91,257 (-€ 9,854). The 
corresponding values for benefit were 2.38 QALYs/person and 1.83 QALYs/person, 
respectively, a difference of 0.55 QALYs over the five year period. This translated into 
a dominant base-case ICER at five years, meaning that rifaximin-α 550mg was both 
less costly and more beneficial. Key parameters that impacted the ICER included 
length of stay in hospital and the number of admissions to hospital. Evaluation to 
10 years also resulted in a dominant ICER, although the lifetime ICER was SEK5,918 
(€ 639) per QALY. cOnclusiOns: In Sweden, treatment with rifaximin-α 550mg 
in patients with recurrent HE in the context of liver cirrhosis was cost effective 
compared to standard care, by reducing episodes of overt HE.
PGI22
eConomIC assessmenT of elTRomboPaG In The TReaTmenT of 
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Objectives: This study aimed to estimate the cost-effectiveness ratio of eltrom-
bopag in the treatment of thrombocytopenia during antiviral therapy (AVT) in 
HCV-patients with advanced liver disease (ALD) in Italy. MethOds: The economic 
assessment was conducted according to a Markov model, which enabled the 
evolution of hypothetical cohorts of patients undergoing different diagnosis and 
treatment protocols and the respective costs and benefits to be quantified. Three 
alternative scenarios were set up: 1) eltrombopag treatment in both enabling phase 
and during AVT; 2) no eltrombopag and no AVT; 3) no eltrombopag treatment and 
administration of a reduced dose of peg-IFN (according to platelet count), and no 
peg-IFN treatment for patients with the lowest platelet count. Parameter uncertainty 
and robustness of the results were assessed through a one-way sensitivity analysis 
and a multivariate probabilistic sensitivity analysis. Results: The results demon-
strate that scenario 1 is associated with a cost per QALY of € 30,020.94 in comparison 
with scenario 2. The ICER reaches a value of 2,752.44 € /QALY when scenario 1 is 
compared with scenario 3. The ICERs therefore are considered sustainable consid-
ering the threshold value generally taken into account by NICE (20,000–40,000 € /
QALY). cOnclusiOns: The use of eltrombopag in thrombocytopenic HCV-patients 
can increase sustained virological response, leading to a reduction in disease pro-
gression and thus a drop in the number of patients with ALD. Preventing the onset 
of complications and acting early to reduce the incidence of complex conditions 
that absorb more resources thus seems a rational choice that is consistent with 
the patient’s preferences and the needs of the healthcare system. This economic 
assessment suggests that eltrombopag administration is indicated.
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Objectives: Ministry of Health, Labour and Welfare of Japan aims for the intro-
duction of Health Technology Assessment in FY2016. Compared to foreign coun-
tries, a lack of resources for conducting the analysis has been pointed out in Japan. 
However, pharmaceutical and medical device industries are urged to seek practical 
approaches utilizing best available resources. The objective of this study was to 
